Blog Posts

Rahul Banerjee: Sequencing immunotherapy for treatment of multiple myeloma

Rahul Banerjee/X

Jan 29, 2025, 10:06

Rahul Banerjee: Sequencing immunotherapy for treatment of multiple myeloma

Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center, shared on X:

“Honor being part of IMWG guidelines about T-cell Tx sequencing in MM – now in Leukemia Journal

! Key among key recommendations:

1 ‘Holding’ therapy as defined entity

2 CAR-T before bsAbs in general. If bsAbs as holding, try for ≥4-week washout pre-collection.

3 No benda!”

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia

Authors: Luciano J. Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Benjamin A. Derman, Maung M. Htut, Chandramouli Nagarajan, Cesar Rodriguez, Joshua Richter, Matthew J. Frigault, Jing C. Ye, Niels W. C. J. van de Donk, Peter M. Voorhees, Benjamin Puliafito, Nizar Bahlis, Rakesh Popat, Wee Joo Chng, P. Joy Ho, Gurbakhash Kaur, Prashant Kapoor, Juan Du, Fredrik Schjesvold, Jesus Berdeja, Hermann Einsele, Adam D. Cohen, Joseph Mikhael, Yelak Biru, S. Vincent Rajkumar, Yi Lin, Thomas G. Martin and Ajai Chari

Rahul Banerjee: Sequencing immunotherapy for treatment of multiple myeloma

Adam D Cohen Ajai Chari Benjamin A. Derman Benjamin Puliafito cancer Cesar Rodriguez Chandramouli Nagarajan Fredrik Schjesvold Gurbakhash Kaur Hermann Einsele Hira Mian Jesus Berdeja Jing C. Ye Joseph Mikhael Joshua Richter Juan Du. Katja Weisel Luciano J Costa Matthew J. Frigault Maung M. Htut Niels W. C. J. van de Donk Nizar Bahlis OncoDaily Oncology P. Joy Ho Peter M. Voorhees Prashant Kapoor Rahul Banerjee Rakesh Popat S Vincent Rajkumar Susan Bal Thomas G Martin Wee Joo Chng Yelak Biru Yi Lin

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...